Anti-musk antibodies for use in treating neuromuscular disorders
Assigneesargenx BV, Universite de Montreal, New York University
InventorsRoeland Vanhauwaert, Karen Silence, Richard Robitaille, Danielle Arbour, Laurence Renaud, Steven J. Burden
Life of this patent
Estimating the term…
Abstract
The present invention relates to an anti-MuSK antibody or antigen binding fragment thereof for use in the treatment of a neuromuscular disorder in a human subject. In an embodiment, this antibody or antigen binding fragment thereof is combined with an anticholinergic compound.
Claims15
1-45. (canceled)
A method of treating a neuromuscular disorder in a human subject, the method comprises administering an anti-MuSK antibody or an antigen-binding fragment thereof.
A method of treating a neuromuscular disorder in a human subject, the method comprising administering an anti-MuSK antibody or fragment thereof, wherein the antibody or fragment thereof comprises:
- (i) a full length heavy chain comprising an amino acid sequence that is at least 80% identical or similar to the amino acid sequence of SEQ ID NO:
- 270 and a full length light chain comprising an amino acid sequence that is at least 80% identical or similar to the amino acid sequence of SEQ ID NO:
- 271, or
- (ii) a full length heavy chain comprising an amino acid sequence that is at least 80% identical or similar to the amino acid sequence of SEQ ID NO:
- 268 and a full length light chain comprising an amino acid sequence that is at least 80% identical or similar to the amino acid sequence of SEQ ID NO:
- 269;
- (iii) wherein the full length heavy chain comprises one or more of the following mutations (all numbered according to the EU numbering system):
- an N297A substitution;
- an N297Q substitution;
- an L234A substitution;
- an L234D substitution;
- an L234E substitution;
- an L234G substitution;
- an L234H substitution;
- an L234F substitution;
- an L234K substitution;
- an L234Q substitution;
- an L234R substitution;
- an L234S substitution;
- an L234T substitution;
- an L235A substitution;
- an L235D substitution;
- an L235E substitution;
- an L235F substitution;
- an L235G substitution;
- an L235V substitution;
- an L235H substitution;
- an L2351 substitution;
- an L235K substitution;
- an L235R substitution;
- an L235S substitution;
- L235T substitution;
- an L235Q substitution;
- an L237A substitution;
- an S239D substitution;
- an E233P substitution;
- an L234V substitution;
- a C236 deletion;
- a G236E substitution;
- a G236R substitution;
- a G236K substitution;
- a G237A substitution;
- a P238A substitution;
- an F243L substitution;
- a D265A substitution;
- an S267E substitution;
- an H268A substitution;
- an R292P substitution;
- a Y300L substitution;
- a K322A substitution;
- a K322Q substitution;
- an A327Q substitution;
- an L328F substitution;
- an L328R substitution;
- a P329A substitution;
- a P329G substitution;
- an A330L substitution;
- an A330S substitution;
- a P331S substitution;
- an 1332E substitution;
- or a P396L substitution.
Dependencies are inferred from the claim text.